Summary
In order to study whether a low molecular weight heparin (LMWH) of mw 4000 D is effective
in the treatment of deep venous thrombosis (DVT), patients with DVT verified by phlebography
were randomized to treatment by continuous intravenous infusion of either unfractionated
heparin (UFH) or LMWH. The initial dose was 240 U (anti F Xa)/kg/12 h. TTiis study
(study I) was stopped because of major bleeding in 2 newly operated patients in the
LMWH group after 27 patients had been treated. The heparin activity measured as F
Xa inhibition assayed in retrospect, was found to be much higher in the LMWH group
(mean 1.6-2.0 anti F Xa U/ml) than in the UFH group (mean 0.5-0.8 anti F Xa U/ml).
A second study was therefore initiated in which the DVT patients were randomly given
UFH (240 U/kg/12 h) or LMWH only 120 U (anti F Xa)/kg/12 h, as initial doses (study
II). In this study 27 patients could be evaluated, the mean heparin activity still
being higher in the LMWH group (0.9-1.2 anti F Xa U/ml) than in the UFH group (0.5-0.7
anti F Xa U/ml).
A second phlebographic investigation showed progression of thrombus size in 3 (11%)
of the UFH patients of studies I and II (n = 29) and improvement in 14 (48%). There
was no progression in any LMWH patient, 6 (50%) had improved in study I and 10 (77%)
in study II. The mean decrease of thrombus size score (according to Marder) during
treatment did not differ between the 3 groups.
Antithrombin III decreased significantly in the UFH group but not in the LMWH groups.
Aminotransferases increased in all 3 groups. There was no difference in mean capillary
bleeding time between the 3 treatment groups.
Although this material is relatively small, our findings suggest that LMWH seems to
be of similar effectivity as UFH.
Key words
Thrombosis - Venous - Treatment - Heparin - Low molecular weight heparin - Phlebography
